Research development of a new GnRH antagonist (Elagolix) for the treatment of endometriosis: a review of the literature

Abstract

Purpose

Limitated studies have reported the efficacy of GnRH antagonist on endometriosis symptoms. The aim of our study was to review all available trials to investigate the medical treatment of endometriosis with only GnRH antagonists, with special attention to pharmacodynamic activity, safety, and efficacy.

Methods

Pub Med and Sciencedirect database were searched using terms of “endometriosis treatment”, “GnRH antagonist”, and “Elagolix”. The search was limited to clinical studies published in English. Title and abstract were screened to identify relevant articles.

Results

Five studies covering use of GnRH antagonist were found. A phase 1 study evaluated the safety, pharmacokinetics, and inhibitory effects on gonadotropins and estradiol of single dose and 7 day elagolix administration to healthy premenopausal women; two phase II studies evaluated efficacy in patient with endometriosis. Moreover, there are two Phase III clinical trials just completed.

Conclusion

GnRH antagonists may have the advantage of oral administration and lower incidence of adverse events. Currently, only Phase II studies have been published demonstrating promising results in terms of efficacy, safety, and tolerability. From the results of the phase III studies, elagolix may become a valuable addition to the armamentarium of pharmacological agents to treat endometriosis-related pain.

This is a preview of subscription content, access via your institution.

References

  1. 1.

    Locci R, Nisolle M, Angioni S, Foidart JM, Munaut C (2013) Expression of the gamma 2 chain of laminin-332 in eutopic and ectopic endometrium of patients with endometriosis. Reprod Biol Endocrinol 11(1):94

    Article  PubMed  PubMed Central  Google Scholar 

  2. 2.

    Pabalan N, Salvador A, Jarjanazi H et al (2014) Association of the progesterone receptor gene polymorphism (PROGINS) with endometriosis: a meta-analysis. Arch Gynecol Obstet 290(5):1015–1022

    CAS  Article  PubMed  Google Scholar 

  3. 3.

    De Cicco Nardone C, Terranova C, Plotti F et al (2015) The role of ovarian fossa evaluation in patients with ovarian endometriosis. Arch Gynecol Obstet 292(4):869–873

    Article  Google Scholar 

  4. 4.

    Mabrouk M, Elmakky A, Caramelli E et al (2012) Performance of peripheral (serum and molecular) blood markers for diagnosis of endometriosis. Arch Gynecol Obstet 285(5):1307–1312

    CAS  Article  PubMed  Google Scholar 

  5. 5.

    Juhaza-Boss I, Fischer C, Lattrich C et al (2011) Endometrial expression of estrogen receptor β and its splice variants in patients with and without endometriosis. Arch Gynecol Obstet 284(4):885–891

    Article  Google Scholar 

  6. 6.

    Scheerer C, Bauer P, Chiantera V, Sehouli J, Kaufmann A, Mechsner S (2016) Characterization of endometriosis-associated immune cell infiltrates (EMaICI). Arch Gynecol Obstet (in press)

  7. 7.

    Mereu L, Florio P, Carri G et al (2012) Clinical outcomes associated with surgical treatment of endometrioma coupled with resection of the posterior broad ligament. Int J Gynaecol Obstet 116(1):57–60

    Article  PubMed  Google Scholar 

  8. 8.

    Pontis A, Arena I, Angioni S (2014) Umbilical endometriosis primary site without pelvic endometriosis and previous surgery: a case report. Giorn It di Ostet Ginecol 24(2):336–338.

    Google Scholar 

  9. 9.

    Melis I, Litta P, Nappi L et al (2015) Sexual function in women with deep endometriosis:correlation with quality of life, intensity of pain, depression, anxiety and body image. Intern J. Sex Health 27:175–185

    Article  Google Scholar 

  10. 10.

    Melis I, Agus M, Pluchino N et al (2014) Alexithymia in women with deep endometriosis? A pilot study. J Endometriosis Pelvic Pain Dis 6:26–33.

    Google Scholar 

  11. 11.

    Mannini L, Sorbi F, Noci I et al (2017) New adverse obstetrics outcomes associated with endometriosis: a retrospective cohort study. Arch Gynecol Obstet 295(1):141–151

  12. 12.

    Angioni S, Cela V, Sedda F et al (2015) Focusing on surgery results in infertile patients with deep endometriosis. Gynecol Endocrinol 31(6):454–457

    Article  PubMed  Google Scholar 

  13. 13.

    Angioni S, Pontis A, Dessole M, Surico D, De Cicco Nardone C, Melis I (2015) Pain control and quality of life after laparoscopic en-block resection of deep infiltrating endometriosis (DIE) vs. incomplete surgical treatment with or without GnRHa administration after surgery. Arch Gynecol Obstet 291(2):363–370

    CAS  Article  PubMed  Google Scholar 

  14. 14.

    Zheng Q, Mao H, Xu Y, Zhao J, Wei X, Liu P (2016) Can postoperative GnRH agonist treatment prevent endometriosis recurrence? A meta-analysis. Arch Gynecol Obstet 294(1):201–207

    CAS  Article  PubMed  Google Scholar 

  15. 15.

    Nappi L, Angioni S, Sorrentino F, Cinnella G, Lombardi M, Greco P (2016) Anti-Mullerian hormone trend evaluation after laparoscopic surgery of monolateral endometrioma using a new dual wavelengths laser system (DWLS) for hemostasis. Gynecol Endocrinol 32(1):34–37

    CAS  Article  PubMed  Google Scholar 

  16. 16.

    Guerriero S, Ajossa S, Gerada M, Virgilio B, Angioni S, Melis GB (2008) Diagnostic value of transvaginal terderness guided ultrasonography for the prediction of location of deep endometriosis. Hum Reprod 23(11):2452–2457

    Article  PubMed  Google Scholar 

  17. 17.

    Angioni S, Nappi L, Pontis A et al (2015) Dienogest. A possible conservative approach in bladder endometriosis. Results of a pilot study. Gynecol Endocrinol 31(5):406–408

    Article  PubMed  Google Scholar 

  18. 18.

    Pontis A, D’Alterio MN, Pirarba S, De Angelis C, Tinelli R, Angioni S (2016) Adenomyosis: a systematic review of medical treatment. Gynecol Endocrinol 1–5

  19. 19.

    Angioni S, Cofelice V, Sedda F, et al (2015) Progestins for symptomatic endometriosis: results of clinical studies. Curr Drug Ther 10(2):91–94.13

    Article  Google Scholar 

  20. 20.

    Ezzati M, Carr BR (2015) Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain. Womens Health (Lond) 11(1):19–28.

    CAS  Article  Google Scholar 

  21. 21.

    Melis GB, Neri M, Corda V et al (2016) Overview of elagolix for the treatment of endometriosis. Expert Opin Drug Metab Toxic 12(5):581–588.

    CAS  Article  Google Scholar 

  22. 22.

    Struthers RS, Nicholls AJ, Grundy J et al (2009) Suppression of gonadotropin and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix. J Clin Endocrinol Metab 94(2):545–551

    CAS  Article  PubMed  Google Scholar 

  23. 23.

    Carr BR (2008) Endometriosis. In: Hoffman BL, Schorge JO, Schaffer JI et al (eds) Williams gynecology. 2nd edn. Chapter. McGraw-Hill, 10. New York

  24. 24.

    Diamond MP, Carr B, Dmowski WP et al (2014) Elagolix treatment for endometriosis-associated pain: results from a phase 2, randomized, double-blind, placebo-controlled study. Reprod Sci 21(3):363–371.

    Article  PubMed  Google Scholar 

  25. 25.

    Carr B, Giudice L, Dmowsky WP et al (2013) Elagolix, an oral GnRH antagonist for endometriosis-associated pain: a randomized controlled study. J Endometr Pelvic Disord 5(3):105–115

    Google Scholar 

  26. 26.

    Surrey E, Giudice LC, Lessey BA et al (2016) Use of elagolix for the managment of endometriosis-associated pain: secondary efficacy results from two randomized, placebo-controlled studies. Fertil Steril 3:e268–e269.

    Article  Google Scholar 

  27. 27.

    Taylor HS, Giudice LC, Lessey BA et al (2016) Elagolix, an oral gonadotropin-realising hormone antagonist, for the management of endometriosis-associated pain: safety and efficacy results from two double-blind, randomized, placebo controlled studies. Fertil Steril 106(3):e271

    Article  Google Scholar 

  28. 28.

    Taylor HS, Surrey E, Soliman AM et al (2016) The impact of elagolix on quality of life in women with endometriosis-associated pain: results from two randomized, placebo-controlled studies using the endometriosis health profile questionnaire. Fertil Steril 106(3):e93

    Article  Google Scholar 

  29. 29.

    Diamond MP, Simon J, Lessey BA et al (2016) The effect of elagolix on the endometrium: safety results from two randomized, placebo-controlled studies in women with endometriosis-associated pain. Fertil Steril 106(3):e94–e95

    Article  Google Scholar 

  30. 30.

    Archer DF, Watts N, Gallagher C et al (2016) The effect of elagolix on bone mineral density: safety results from two randomized, placebo-controlled studies in women with endometriosis associated pain. Fertil Steril 106(3):e276–e277

    Article  Google Scholar 

  31. 31.

    Angioni S, Cofelice V, Pontis A, Tinelli R, Socolov R (2014) New trends of progestins treatment of endometriosis. Gynecol Endocrinol 30(11):769–773

    CAS  Article  PubMed  Google Scholar 

Download references

Author contributions

Protocol/project development Angioni S, Melis GB. Data collection or management Pontis A, Nappi L. Data analysis Pontis A, Paoletti AM. Manuscript writing Pontis A, Sorrentino F.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Pontis Alessandro.

Ethics declarations

Conflict of interest

Authors declare that have not conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals part performed by any of the authors.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Alessandro, P., Luigi, N., Felice, S. et al. Research development of a new GnRH antagonist (Elagolix) for the treatment of endometriosis: a review of the literature. Arch Gynecol Obstet 295, 827–832 (2017). https://doi.org/10.1007/s00404-017-4328-6

Download citation

Keywords

  • Endometriosis treatment
  • GnRH antagonist
  • Elagolix